David A Pattison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2259527/publications.pdf

Version: 2024-02-01

51 papers 2,036 citations

20 h-index 254184 43 g-index

56 all docs 56 does citations

56 times ranked 2062 citing authors

#	Article	IF	CITATIONS
1	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.	13.7	552
2	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 857-865.	5.0	191
3	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021, 80, 682-689.	1.9	181
4	68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging, 2016, 16, 22.	2.8	135
5	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3278-3287.	3.6	125
6	⁶⁴ Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2019, 60, 777-785.	5.0	98
7	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Thyroid, 2019, 29, 1634-1645.	4.5	69
8	68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 477-482.	6.4	54
9	Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for nonâ€metastatic prostate cancer: implementation of standardized management guidelines. Andrology, 2013, 1, 583-589.	3.5	49
10	TheraP: ¹⁷⁷ Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxelâ€"Overall survival after median follow-up of 3 years (ANZUP 1603) Journal of Clinical Oncology, 2022, 40, 5000-5000.	1.6	44
11	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 476-489.	6.4	42
12	Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4495-4507.	6.4	41
13	Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 2017, 24, R203-R221.	3.1	36
14	Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68ÂGa]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 763-776.	6.4	36
15	¹⁸ F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 2018, 59, 749-755.	5.0	35
16	UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Luâ€PSMAâ€617 and docetaxel vs docetaxel in metastatic hormoneâ€naà ve prostate cancer (clinical trial protocol). BJU International, 2021, 128, 331-342.	2.5	33
17	Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nuclear Medicine Communications, 2015, 36, 356-362.	1.1	27
18	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. Journal of Nuclear Medicine, 2021, 62, 1278-1284.	5.0	25

#	Article	IF	Citations
19	Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Annals of Clinical Biochemistry, 2008, 45, 520-523.	1.6	22
20	Strongyloidiasis in personnel of the Regional Assistance Mission to Solomon Islands (RAMSI). Medical Journal of Australia, 2008, 189, 203-206.	1.7	22
21	Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. PET Clinics, 2015, 10, 461-476.	3.0	21
22	The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 66.e1-66.e9.	1.6	20
23	Diagnostic challenges in a patient with an occult insulinoma: ^{68Â} Gaâ€ <scp>DOTA</scp> â€exendinâ€4 <scp>PET</scp> / <scp>CT</scp> and ⁶⁸ Gaâ€ <scp>DOTATATE PET</scp> / <scp>CT</scp> . Clinical Case Reports (discontinued), 2018, 6.719-722.	0.5	14
24	Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. Advances in Urology, 2021, 2021, 1-9.	1.3	13
25	Enhanced White Adipose Tissue Metabolism in latrogenic Cushing's Syndrome With FDG PET/CT. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3041-3042.	3.6	11
26	The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. Cancer Imaging, 2020, 20, 68.	2.8	11
27	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)â€"Final results Journal of Clinical Oncology, 2022, 40, 4122-4122.	1.6	11
28	A New Theranostic Paradigm for Advanced Thyroid Cancer. Journal of Nuclear Medicine, 2016, 57, 1493-1494.	5.0	10
29	Amiodarone-Induced Destructive Thyroiditis Associated with Coronary Artery Vasospasm and Recurrent Ventricular Fibrillation. European Thyroid Journal, 2012, 2, 65-7.	2.4	9
30	PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clinical Endocrinology, 2021, 95, 13-28.	2.4	9
31	Utility of <scp>⁶⁸Gaâ€DOTAâ€Exendin</scp> â€4 positron emission tomography–computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. Internal Medicine Journal, 2021, 51, 1657-1664.	0.8	9
32	The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. Journal of Nuclear Medicine, 2022, 63, 819-822.	5.0	9
33	Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urologic Oncology: Seminars and Original Investigations, 2022, 40, 276.e1-276.e9.	1.6	8
34	An Endocrine Cause of Acute Post-partum Hypertension. Obstetric Medicine, 2013, 6, 30-32.	1.1	7
35	Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Research, 2019, 9, 15.	2.5	7
36	124I-PET/CT–Guided Diagnosis and Personalized Treatment of Metastatic Papillary Thyroid Cancer to the Pancreas. Clinical Nuclear Medicine, 2021, 46, 337-339.	1.3	7

#	Article	IF	Citations
37	Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. EJNMMI Research, 2021, 11, 128.	2.5	6
38	Localisation of occult extraâ€pancreatic insulinoma using glucagonâ€like peptideâ€1 receptor molecular imaging. Internal Medicine Journal, 2018, 48, 97-98.	0.8	4
39	Lymphangitic Carcinomatosis From Prostate Cancer Identified With Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography Imaging. Urology, 2018, 114, e1-e2.	1.0	4
40	THYROPET Study: Is It Biology or Technology That Is the Issue?. Journal of Nuclear Medicine, 2017, 58, 354.1-354.	5.0	3
41	Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. Journal of Critical Care, 2020, 60, 319-322.	2.2	3
42	[18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD. Bone Marrow Transplantation, 2022, 57, 517-519.	2.4	3
43	Exerciseâ€associated hyponatraemia on the Kokoda Track. Medical Journal of Australia, 2011, 194, 247-248.	1.7	2
44	Intense focal pituitary FDG uptake due to intravascular large Bâ€cell lymphoma in pyrexia of unknown origin. American Journal of Hematology, 2016, 91, 1167-1168.	4.1	2
45	Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRI. Clinical Nuclear Medicine, 2021, 46, e448-e450.	1.3	2
46	All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others. European Urology Oncology, 2022, 5, 283-284.	5.4	2
47	99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis. Clinical Nuclear Medicine, 2022, 47, e582-e584.	1.3	2
48	Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. Clinical Nuclear Medicine, 2018, 43, 186-187.	1.3	1
49	Intracoronary 99m Tc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography for Preoperative Evaluation of At-Risk Myocardium. Circulation, 2013, 128, 567-570.	1.6	0
50	Management of Distant Metastasis in Differentiated Thyroid Cancer. , 2018, , 121-140.		0
51	Targeted Molecular Imaging of Translocator Protein (TSPO) Using 18FGE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). Blood, 2018, 132, 3397-3397.	1.4	0